|
1. World health organization: Globocan 2012.
2. 行政院衛生署國民健康局: <99 年癌症登記報告.pdf>. 2013.10.
3. Inoue M, Tsugane S: Epidemiology of gastric cancer in Japan. Postgrad Med J 2005, 81:419-424.
4. Hu Z, Ajani JA, Wei Q: Molecular epidemiology of gastric cancer: current status and future
prospects. Gastrointest Cancer Res 2007, 1:12-19.
5. Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003,
56:1-9.
6. Hudler P, Kocevar N, Komel R: Proteomic approaches in biomarker discovery: new perspectives
in cancer diagnostics. ScientificWorldJournal 2014, 260348.
7. Wu W, Juan WC, Liang CR, Yeoh KG, So J, Chung MC: S100A9, GIF and AAT as potential
combinatorial biomarkers in gastric cancer diagnosis and prognosis. Proteomics Clin Appl 2012,
6:152-162.
8. Ebert MP, Rocken C: Molecular screening of gastric cancer by proteome analysis. Eur J
Gastroenterol Hepatol 2006, 18:847-853.
9. .
10. Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N, Maruyama M: Tumor markers CEA,
CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with
advanced gastric cancer. Jpn J Clin Oncol 1999, 29:550-555.
11. Lai IR, Lee WJ, Huang MT, Lin HH: Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125
levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 2002,
49:1157-1160.
12. Li Y, Yang Y, Lu M, Shen L: Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis
of recurrence after radical resection of gastric cancer. Hepatogastroenterology 2011,
58:2166-2170.
13. Chong PK, Lee H, Zhou J, Liu SC, Loh MC, Wang TT, Chan SP, Smoot DT, Ashktorab H, So JB, et al:
ITIH3 is a potential biomarker for early detection of gastric cancer. J Proteome Res 2010,
9:3671-3679.
14. Liu W, Liu B, Xin L, Zhang Y, Chen X, Zhu Z, Lin Y: Down-regulated expression of complement
factor I: a potential suppressive protein for gastric cancer identified by serum proteome
analysis. Clin Chim Acta 2007, 377:119-126.
15. Chong PK, Lee H, Loh MC, Choong LY, Lin Q, So JB, Lim KH, Soo RA, Yong WP, Chan SP, et al:
Upregulation of plasma C9 protein in gastric cancer patients. Proteomics 2010, 10:3210-3221.
16. Hao Y, Yu Y, Wang L, Yan M, Ji J, Qu Y, Zhang J, Liu B, Zhu Z: IPO-38 is identified as a novel serum
biomarker of gastric cancer based on clinical proteomics technology. J Proteome Res 2008,
7:3668-3677.
56
17. Bones J, Byrne JC, O''Donoghue N, McManus C, Scaife C, Boissin H, Nastase A, Rudd PM:
Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals
potential markers arising from host defense response mechanisms. J Proteome Res 2011,
10:1246-1265.
18. Kon OL, Yip TT, Ho MF, Chan WH, Wong WK, Tan SY, Ng WH, Kam SY, Eng A, Ho P, et al: The
distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile.
BMC Med Genomics 2008, 1-54.
19. Hsu PI, Chen CH, Hsieh CS, Chang WC, Lai KH, Lo GH, Hsu PN, Tsay FW, Chen YS, Hsiao M, et al:
Alpha1-antitrypsin precursor in gastric juice is a novel biomarker for gastric cancer and ulcer.
Clin Cancer Res 2007, 13:876-883.
20. Kam SY, Hennessy T, Chua SC, Gan CS, Philp R, Hon KK, Lai L, Chan WH, Ong HS, Wong WK, et al:
Characterization of the human gastric fluid proteome reveals distinct pH-dependent protein
profiles: implications for biomarker studies. J Proteome Res 2011, 10:4535-4546.
21. Tsunemi S, Nakanishi T, Fujita Y, Bouras G, Miyamoto Y, Miyamoto A, Nomura E, Takubo T,
Tanigawa N: Proteomics-based identification of a tumor-associated antigen and its
corresponding autoantibody in gastric cancer. Oncol Rep 2010, 23:949-956.
22. Chen YR, Juan HF, Huang HC, Huang HH, Lee YJ, Liao MY, Tseng CW, Lin LL, Chen JY, Wang MJ, et
al: Quantitative proteomic and genomic profiling reveals metastasis-related protein
expression patterns in gastric cancer cells. J Proteome Res 2006, 5:2727-2742.
23. Guo T, Zhu Y, Gan CS, Lee SS, Zhu J, Wang H, Li X, Christensen J, Huang S, Kon OL, Sze SK:
Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET
kinase inhibitor in cancer cells. Mol Cell Proteomics 2010, 9:2629-2641.
24. Torti D, Sassi F, Galimi F, Gastaldi S, Perera T, Comoglio PM, Trusolino L, Bertotti A: A preclinical
algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the
MET oncogene in gastric tumors. Int J Cancer 2012, 130:1357-1366.
25. Yan GR, Xu SH, Tan ZL, Yin XF, He QY: Proteomics characterization of gastrokine 1-induced
growth inhibition of gastric cancer cells. Proteomics 2011, 11:3657-3664.
26. Uppal DS, Powell SM: Genetics/genomics/proteomics of gastric adenocarcinoma.
Gastroenterol Clin North Am 2013, 42:241-260.
27. Wu W, Chung MC: The gastric fluid proteome as a potential source of gastric cancer
biomarkers. J Proteomics 2013, 90:3-13.
28. Lam KW, Lo SC: Discovery of diagnostic serum biomarkers of gastric cancer using proteomics.
Proteomics Clin Appl 2008, 2:219-228.
29. Lin LL, Huang HC, Juan HF: Discovery of biomarkers for gastric cancer: a proteomics approach.
J Proteomics 2012, 75:3081-3097.
30. Ren H, Du N, Liu G, Hu HT, Tian W, Deng ZP, Shi JS: Analysis of variabilities of serum proteomic
spectra in patients with gastric cancer before and after operation. World J Gastroenterol 2006,
12:2789-2792.
57
31. Oue N, Sentani K, Noguchi T, Ohara S, Sakamoto N, Hayashi T, Anami K, Motoshita J, Ito M,
Tanaka S, et al: Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly
sensitive biomarker for gastric cancer patients. Int J Cancer 2009, 125:2383-2392.
32. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT: Plasma matrix
metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict
gastric cancer evolution. Clin Cancer Res 2007, 13:2054-2060.
33. Umemura H, Togawa A, Sogawa K, Satoh M, Mogushi K, Nishimura M, Matsushita K, Tanaka H,
Takizawa H, Kodera Y, Nomura F: Identification of a high molecular weight kininogen fragment
as a marker for early gastric cancer by serum proteome analysis. J Gastroenterol 2011,
46:577-585.
34. Lim JY, Cho JY, Paik YH, Chang YS, Kim HG: Diagnostic application of serum proteomic patterns
in gastric cancer patients by ProteinChip surface-enhanced laser desorption/ionization
time-of-flight mass spectrometry. Int J Biol Markers 2007, 22:281-286.
35. Liang Y, Fang M, Li J, Liu CB, Rudd JA, Kung HF, Yew DT: Serum proteomic patterns for gastric
lesions as revealed by SELDI mass spectrometry. Exp Mol Pathol 2006, 81:176-180.
36. Edberg DD, Bruce JE, Siems WF, Reeves R: In vivo posttranslational modifications of the high
mobility group A1a proteins in breast cancer cells of differing metastatic potential.
Biochemistry 2004, 43:11500-11515.
37. Ohyama C: Glycosylation in bladder cancer. Int J Clin Oncol 2008, 13:308-313.
38. Chen G, Wang H, Gharib TG, Huang CC, Thomas DG, Shedden KA, Kuick R, Taylor JM, Kardia SL,
Misek DE, et al: Overexpression of oncoprotein 18 correlates with poor differentiation in lung
adenocarcinomas. Mol Cell Proteomics 2003, 2:107-116.
39. Kossowska B, Ferens-Sieczkowska M, Gancarz R, Passowicz-Muszynska E, Jankowska R:
Fucosylation of serum glycoproteins in lung cancer patients. Clin Chem Lab Med 2005,
43:361-369.
40. Kalsheker N, Morley S, Morgan K: Gene regulation of the serine proteinase inhibitors
alpha1-antitrypsin and alpha1-antichymotrypsin. Biochem Soc Trans 2002, 30:93-98.
41. Travis J, Salvesen GS: Human plasma proteinase inhibitors. Annu Rev Biochem 1983,
52:655-709.
42. 王丽敏 骆肖赵: 中性粒细胞弹性蛋白酶在慢性阻塞性肺疾病发病中的作用. Tianjin Med J,
Apr 2012,Vol 40 No 4.
43. Karnaukhova E: Recent Advances in the Research and Development of Alpha-1 Proteinase
Inhibitor for Therapeutic Use. Lung Diseases - Selected State of the Art Reviews 2012.
44. El-Akawi ZJ, Al-Hindawi FK, Bashir NA: Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung,
prostate and breast cancer patients. Neuro Endocrinol Lett 2008, 29:482-484.
45. El-Akawi ZJ, Abu-Awad AM, Sharara AM, Khader Y: The importance of alpha-1 antitrypsin
(alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate
cancer patients. Neuro Endocrinol Lett 2010, 31:113-116.
58
46. Trachte AL, Suthers SE, Lerner MR, Hanas JS, Jupe ER, Sienko AE, Adesina AM, Lightfoot SA,
Brackett DJ, Postier RG: Increased expression of alpha-1-antitrypsin, glutathione S-transferase
pi and vascular endothelial growth factor in human pancreatic adenocarcinoma. Am J Surg
2002, 184:642-647; discussion 647-648.
47. Solakidi S, Dessypris A, Stathopoulos GP, Androulakis G, Sekeris CE: Tumour-associated trypsin
inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and
alpha1-antitrypsin in patients with gastrointestinal malignancies. Clin Biochem 2004,
37:56-60.
48. Hong WS, Hong SI: Clinical usefulness of alpha-1-antitrypsin in the diagnosis of hepatocellular
carcinoma. J Korean Med Sci 1991, 6:206-213.
49. Bernacka K, Kuryliszyn-Moskal A, Sierakowski S: The levels of alpha 1-antitrypsin and alpha
1-antichymotrypsin in the sera of patients with gastrointestinal cancers during diagnosis.
Cancer 1988, 62:1188-1193.
50. Tountas Y, Sparos L, Theodoropoulos C, Trichopoulos D: Alpha 1-antitrypsin and cancer of the
pancreas. Digestion 1985, 31:37-40.
51. Lin CY, Wang V, Shui HA, Juang RH, Hour AL, Chen PS, Huang HM, Wu SY, Lee JC, Tsai TL, Chen
HM: A comprehensive evaluation of imidazole-zinc reverse stain for current proteomic
researches. Proteomics 2009, 9:696-709.
52. Eric S Witze1, William M Old1,3, Katheryn A Resing1 & Natalie G Ahn1,2: Mapping protein
post-translational modifications with mass spectrometry. Nature 2007
53. Larsen M, Trelle M, Thingholm T, Jensen O: Analysis of posttranslational modifications of
proteins by tandem mass spectrometry. BioTechniques 2006, 40:790-798.
54. Arnold K, Bordoli L, Kopp J, Schwede T: The SWISS-MODEL workspace: a web-based
environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201.
55. Schwede T, Kopp J, Guex N, Peitsch MC: SWISS-MODEL: An automated protein
homology-modeling server. Nucleic Acids Res 2003, 31:3381-3385.
56. Guex N, Peitsch MC: SWISS-MODEL and the Swiss-PdbViewer: an environment for
comparative protein modeling. Electrophoresis 1997, 18:2714-2723.
57. Kuster B, Krogh TN, Mortz E, Harvey DJ: Glycosylation analysis of gel-separated proteins.
Proteomics 2001, 1:350-361.
58. Aebersold R, Goodlett DR: Mass spectrometry in proteomics. Chem Rev 2001, 101:269-295.
59. Teng-umnuay P, Morris HR, Dell A, Panico M, Paxton T, West CM: The cytoplasmic F-box binding
protein SKP1 contains a novel pentasaccharide linked to hydroxyproline in Dictyostelium. J
Biol Chem 1998, 273:18242-18249.
60. Lacko AG, Reason AJ, Nuckolls C, Kudchodkar BJ, Nair MP, Sundarrajan G, Pritchard PH, Morris
HR, Dell A: Characterization of recombinant human plasma lecithin: cholesterol
acyltransferase (LCAT): N-linked carbohydrate structures and catalytic properties. J Lipid Res
1998, 39:807-820.
59
61. Dennis JW, Granovsky M, Warren CE: Glycoprotein glycosylation and cancer progression.
Biochim Biophys Acta 1999, 1473:21-34.
62. Abd Hamid UM, Royle L, Saldova R, Radcliffe CM, Harvey DJ, Storr SJ, Pardo M, Antrobus R,
Chapman CJ, Zitzmann N, et al: A strategy to reveal potential glycan markers from serum
glycoproteins associated with breast cancer progression. Glycobiology 2008, 18:1105-1118.
63. Qu Y, Dang S, Hou P: Gene methylation in gastric cancer. Clin Chim Acta 2013, 424:53-65.
64. Kohnlein T, Welte T: Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation,
diagnosis, and treatment. Am J Med 2008, 121:3-9.
65. Chhetri SK: Alpha-1-antitrypsin deficiency and increased lung cancer risk. Thorax November
2008, 63:950.
66. Eriksson S, Carlson J, Velez R: Risk of Cirrhosis and Primary Liver Cancer in Alpha1-Antitrypsin
Deficiency. New England Journal of Medicine 1986, 314:736-739.
67. Ganji SM, Sahebghadam-Lotfi A, Rastgar-Jazii F, Yazdanbod M, Mota A, Mohsenifar A,
Kazemnejad A: Alpha-1 Antitrypsin Deficient Squamous Cell Carcinoma of Esophagus in the
Azeri Population of Iran: Correlation of Genotype With Phenotype and Survival. Laboratory
Medicine 2010, 41:613-618.
68. Hsu PI, Chen CH, Hsiao M, Wu DC, Lin CY, Lai KH, Lu PJ: Diagnosis of gastric malignancy using
gastric juice alpha1-antitrypsin. Cancer Epidemiol Biomarkers Prev 2010, 19:405-411.
69. Lopez-Arias E, Aguilar-Lemarroy A, Felipe Jave-Suarez L, Morgan-Villela G, Mariscal-Ramirez I,
Martinez-Velazquez M, Alvarez AH, Gutierrez-Ortega A, Hernandez-Gutierrez R: Alpha
1-antitrypsin: a novel tumor-associated antigen identified in patients with early-stage breast
cancer. Electrophoresis 2012, 33:2130-2137.
70. Yang P, Cunningham JM, Halling KC, Lesnick TG, Burgart LJ, Wiegert EM, Christensen ER, Lindor
NM, Katzmann JA, Thibodeau SN: Higher risk of mismatch repair-deficient colorectal cancer in
alpha(1)-antitrypsin deficiency carriers and cigarette smokers. Mol Genet Metab 2000,
71:639-645.
71. Yang N, Feng S, Shedden K, Xie X, Liu Y, Rosser CJ, Lubman DM, Goodison S: Urinary
glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free
quantification. Clin Cancer Res 2011, 17:3349-3359.
72. KRYSTYNA BERNACKA M, PHD, ANNA KURYLISZYN-MOSKAL, MD, PHD, AND STANISLAW
SIERAKOWSKI, MD, PHD -Antichymotrypsin.pdf>. Cancer 1988., 62:1188-1193.
73. Hong WS HS: Clinical usefulness of alpha-1-antitrypsin in the diagnosis of hepatocellular
carcinoma. J Korean Med Sci 1991, 6(3)::206-213.
74. Latner AL, Turner GA, Lamin MM: Plasma alpha-1-antitrypsin levels in early and late carcinoma
of the cervix. Oncology 1976, 33:12-14.
75. Thompson DK, Haddow JE, Smith DE, Ritchie RF: Elevated serum acute phase protein levels as
predictors of disseminated breast cancer. Cancer 1983, 51:2100-2104.
60
76. Bates SE, Longo DL: Tumor markers: value and limitations in the management of cancer
patients. Cancer Treat Rev 1985, 12:163-207.
77. Hamrita B, Chahed K, Trimeche M, Guillier CL, Hammann P, Chaieb A, Korbi S, Chouchane L:
Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel
serum markers in infiltrating ductal breast carcinomas. Clin Chim Acta 2009, 404:111-118.
78. Semaan SM, Wang X, Marshall AG, Sang QX: Identification of Potential Glycoprotein
Biomarkers in Estrogen Receptor Positive (ER+) and Negative (ER-) Human Breast Cancer
Tissues by LC-LTQ/FT-ICR Mass Spectrometry. J Cancer 2012, 3:269-284.
79. Krishnan B, Gierasch LM: Dynamic local unfolding in the serpin alpha-1 antitrypsin provides a
mechanism for loop insertion and polymerization. Nat Struct Mol Biol 2011, 18:222-226.
80. Hood DB, Huntington JA, Gettins PG: Alpha 1-proteinase inhibitor variant T345R. Influence of
P14 residue on substrate and inhibitory pathways. Biochemistry 1994, 33:8538-8547.
81. Lawrence DA, Olson ST, Muhammad S, Day DE, Kvassman JO, Ginsburg D, Shore JD: Partitioning
of serpin-proteinase reactions between stable inhibition and substrate cleavage is regulated
by the rate of serpin reactive center loop insertion into beta-sheet A. J Biol Chem 2000,
275:5839-5844.
82. Hagglof P, Bergstrom F, Wilczynska M, Johansson LB, Ny T: The reactive-center loop of active
PAI-1 is folded close to the protein core and can be partially inserted. J Mol Biol 2004,
335:823-832.
83. Hejgaard J: Inhibitory serpins from rye grain with glutamine as P1 and P2 residues in the
reactive center. FEBS Lett 2001, 488:149-153.
84. Halim A, Nilsson J, Ruetschi U, Hesse C, Larson G: Human urinary glycoproteomics; attachment
site specific analysis of N- and O-linked glycosylations by CID and ECD. Mol Cell Proteomics
2012, 11:M111 013649.
85. Kristiansen TZ, Bunkenborg J, Gronborg M, Molina H, Thuluvath PJ, Argani P, Goggins MG,
Maitra A, Pandey A: A proteomic analysis of human bile. Mol Cell Proteomics 2004, 3:715-728.
86. Lewandrowski U, Moebius J, Walter U, Sickmann A: Elucidation of N-glycosylation sites on
human platelet proteins: a glycoproteomic approach. Mol Cell Proteomics 2006, 5:226-233.
87. Kolarich D, Weber A, Turecek PL, Schwarz HP, Altmann F: Comprehensive glyco-proteomic
analysis of human alpha1-antitrypsin and its charge isoforms. Proteomics 2006, 6:3369-3380.
88. Jia W, Lu Z, Fu Y, Wang HP, Wang LH, Chi H, Yuan ZF, Zheng ZB, Song LN, Han HH, et al: A strategy
for precise and large scale identification of core fucosylated glycoproteins. Mol Cell Proteomics
2009, 8:913-923.
89. Plumbridge J, Vimr E: Convergent pathways for utilization of the amino sugars
N-acetylglucosamine, N-acetylmannosamine, and N-acetylneuraminic acid by Escherichia coli.
J Bacteriol 1999, 181:47-54.
90. Fuster MM, Esko JD: The sweet and sour of cancer: glycans as novel therapeutic targets. Nat
Rev Cancer 2005, 5:526-542.
61
91. Vimr ER, Troy FA: Identification of an inducible catabolic system for sialic acids (nan) in
Escherichia coli. J Bacteriol 1985, 164:845-853.
92. Park JH, Kim TY, Jong HS, Kim TY, Chun YS, Park JW, Lee CT, Jung HC, Kim NK, Bang YJ: Gastric
epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible
factor-1alpha in gastric cancer cells. Clin Cancer Res 2003, 9:433-440.
93. Strahl BD, Allis CD: The language of covalent histone modifications. Nature 2000, 403:41-45.
94. Sprung R, Chen Y, Zhang K, Cheng D, Zhang T, Peng J, Zhao Y: Identification and validation of
eukaryotic aspartate and glutamate methylation in proteins. J Proteome Res 2008,
7:1001-1006.
95. Zhou W, Capello M, Fredolini C, Piemonti L, Liotta LA, Novelli F, Petricoin EF: Mass spectrometry
analysis of the post-translational modifications of alpha-enolase from pancreatic ductal
adenocarcinoma cells. J Proteome Res 2010, 9:2929-2936.
96. Oya-Ito T, Naito Y, Takagi T, Handa O, Matsui H, Yamada M, Shima K, Yoshikawa T: Heat-shock
protein 27 (Hsp27) as a target of methylglyoxal in gastrointestinal cancer. Biochim Biophys
Acta 2011, 1812:769-781.
97. Wada Y, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K: Relationship between Helicobacter
pylori tyrosine-phosphorylated CagA-related markers and the development of diffuse-type
gastric cancers: a case-control study. Digestion 2010, 82:10-17.
98. Lee SH, Kim J, Kim WH, Lee YM: Hypoxic silencing of tumor suppressor RUNX3 by histone
modification in gastric cancer cells. Oncogene 2009, 28:184-194.
99. Bergin DA, Reeves EP, Meleady P, Henry M, McElvaney OJ, Carroll TP, Condron C, Chotirmall SH,
Clynes M, O''Neill SJ, McElvaney NG: alpha-1 Antitrypsin regulates human neutrophil
chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest 2010, 120:4236-4250.
100. Yasumoto K, Okamoto S, Mukaida N, Murakami S, Mai M, Matsushima K: Tumor necrosis factor
alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric
cancer cell line through acting concurrently on AP-1 and NF-kB-like binding sites of the
interleukin 8 gene. J Biol Chem 1992, 267:22506-22511.
101. Uen YH, Lin KY, Sun DP, Liao CC, Hsieh MS, Huang YK, Chen YW, Huang PH, Chen WJ, Tai CC, et al:
Comparative proteomics, network analysis and post-translational modification identification
reveal differential profiles of plasma Con A-bound glycoprotein biomarkers in gastric cancer. J
Proteomics 2013, 83:197-213.
|